Walter and Eliza Hall Institute of Medical Research
His main research concerns Cancer, Programmed cell death, Apoptosis, Cancer research and Pharmacology. His Cancer study combines topics in areas such as Myeloid Cell Leukemia Sequence 1 Protein, Bcl-2 Homologous Antagonist-Killer Protein and Oncology. His Programmed cell death study frequently draws connections between related disciplines such as Cell biology.
His biological study spans a wide range of topics, including Protein structure and Intrinsic apoptosis. Guillaume Lessene has researched Cancer research in several fields, including Venetoclax and Protein family. His Pharmacology research includes themes of Bcl-xL and Leukemia.
His scientific interests lie mostly in Cancer research, Programmed cell death, Apoptosis, Cell biology and Cancer. The concepts of his Cancer research study are interwoven with issues in Hematology, Internal medicine, Venetoclax, Bcl-xL and MCL1. He works in the field of Programmed cell death, focusing on Intrinsic apoptosis in particular.
His Apoptosis study also includes fields such as
Plasma protein binding which connect with Binding site,
In vitro that connect with fields like Colorectal cancer. His Cell biology research is multidisciplinary, incorporating elements of Bcl-2 Homologous Antagonist-Killer Protein and Necroptosis. His Cancer study also includes
BH3 Mimetic ABT-737 most often made with reference to Pharmacology,
Stereochemistry which intersects with area such as Combinatorial chemistry.
Guillaume Lessene mainly focuses on Cancer research, Venetoclax, Bcl-xL, Small molecule and Programmed cell death. Guillaume Lessene has included themes like Cytotoxic T cell, In vitro, Mitosis, Cell division and Colorectal cancer in his Cancer research study. His Venetoclax research includes elements of Hematology, MCL1 and Bh3 mimetics.
Bcl-xL is a subfield of Apoptosis that he explores. His research integrates issues of Ovarian cancer, Neuroblastoma and Phosphorylation in his study of Programmed cell death. His RIPK1 research integrates issues from Serine, Protein kinase A, Photoaffinity labeling and Effector, Cell biology.
His primary areas of study are Cell biology, Binding site, Protease, Ubiquitin and ISG15. His Cell biology study combines topics from a wide range of disciplines, such as Programmed cell death, RIPK1 and Necroptosis. His Programmed cell death research is multidisciplinary, relying on both Transport protein, Cell junction, Cell membrane, Tight junction and Effector.
His Necroptosis study integrates concerns from other disciplines, such as Photoaffinity labeling, Serine and Protein kinase A. Guillaume Lessene has included themes like Protein structure, Innate immune system and Viral replication in his Binding site study. His Protease research encompasses a variety of disciplines, including Small molecule, Biochemistry, Papain and Proteases.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Peter E Czabotar;Guillaume Lessene;Andreas Strasser;Jerry M Adams.
Nature Reviews Molecular Cell Biology (2014)
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
András Kotschy;Zoltán Szlavik;James Murray;James Davidson.
BCL-2 family antagonists for cancer therapy
Guillaume Lessene;Peter E. Czabotar;Peter M. Colman.
Nature Reviews Drug Discovery (2008)
Apoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I IFN Production
Michael J. White;Michael J. White;Kate McArthur;Kate McArthur;Donald Metcalf;Donald Metcalf;Rachael M. Lane.
Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death
Joanne M. Hildebrand;Maria C. Tanzer;Isabelle S. Lucet;Isabelle S. Lucet;Samuel N. Young.
Proceedings of the National Academy of Sciences of the United States of America (2014)
BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis
Kate McArthur;Kate McArthur;Kate McArthur;Lachlan W. Whitehead;Lachlan W. Whitehead;John M. Heddleston;Lucy Li.
Structure-guided design of a selective BCL-XL inhibitor
Guillaume Lessene;Guillaume Lessene;Peter Edward Czabotar;Peter Edward Czabotar;Brad Sleebs;Brad Sleebs;Kerry Zobel.
Nature Chemical Biology (2013)
Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2.
Theresa Klemm;Gregor Ebert;Dale J Calleja;Cody C Allison.
The EMBO Journal (2020)
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity
Zhi-Fu Tao;Lisa Hasvold;Le Wang;Xilu Wang.
ACS Medicinal Chemistry Letters (2014)
BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.
Delphine Merino;Gemma L. Kelly;Guillaume Lessene;Andrew H. Wei.
Cancer Cell (2018)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: